Personalis (NASDAQ:PSNL) Trading Down 9.3% – Should You Sell?

Shares of Personalis, Inc. (NASDAQ:PSNL) were down 9.3% during mid-day trading on Friday . The company traded as low as $6.66 and last traded at $6.6380. Approximately 627,854 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 1,402,346 shares. The stock had previously closed at $7.32.

Analyst Ratings Changes

A number of research analysts have recently weighed in on PSNL shares. Morgan Stanley cut their price target on Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Needham & Company LLC lifted their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. BTIG Research upped their price objective on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Finally, Guggenheim raised their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Personalis Stock Down 11.5%

The company’s fifty day simple moving average is $8.54 and its two-hundred day simple moving average is $8.34. The company has a market capitalization of $677.49 million, a price-to-earnings ratio of -7.12 and a beta of 2.02.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. Equities research analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Several large investors have recently modified their holdings of the business. AIGH Capital Management LLC grew its position in shares of Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after purchasing an additional 168,143 shares during the period. Oracle Investment Management Inc. acquired a new stake in shares of Personalis in the third quarter valued at about $1,496,000. Aberdeen Group plc raised its holdings in Personalis by 35.7% during the third quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock worth $15,569,000 after acquiring an additional 628,450 shares in the last quarter. Geode Capital Management LLC raised its holdings in Personalis by 165.6% during the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after acquiring an additional 851,422 shares in the last quarter. Finally, ARK Investment Management LLC boosted its position in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after purchasing an additional 802,268 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.